471 results on '"Pernod, Gilles"'
Search Results
2. Venous recanalisation in the setting of post-thrombotic syndrome: An expert consensus from the French Society of Vascular Medicine (SFMV) and the French Society of Cardiovascular Imaging and Interventional Radiology (SFICV)
3. Update on the diagnosis of recurrence of lower limb deep vein thrombosis. A Consensus statement of the French Society for Vascular Medicine (SFMV)
4. Traduction et republication de : « Événements thromboemboliques artériels liés au cancer »
5. Update About the Management of Low-Density Lipoprotein Cholesterol and Hypertriglyceridemia in Lower Extremity Peripheral Artery Disease Patients: Consensus of the French Society of Vascular Medicine and the French Society for Vascular and Endovascular Surgery
6. Outpatient management of cancer-associated pulmonary embolism: A post-hoc analysis from the HOME-PE trial
7. Cancer-related arterial thromboembolic events
8. Management of venous thromboembolic disease in patients with malignant brain tumours
9. Frequency and predictors for chronic thromboembolic pulmonary hypertension after a first unprovoked pulmonary embolism: Results from PADIS studies
10. Comparative evaluation of socioeconomic insecurity in peripheral and coronary artery disease patients
11. Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin
12. Patients treated with vitamin K oral anticoagulants in family practice: a new approach to bleeding risk assessment. An ancillary study by the CACAO prospective general practice cohort.
13. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial
14. Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin
15. Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination
16. Compliance with Early Long-Term Prophylaxis Guidelines for Severe Hemophilia A
17. Disparities Between International Guidelines (AHA/ESC/ESVS/ESVM/SVS) Concerning Lower Extremity Arterial Disease: Consensus of the French Society of Vascular Medicine (SFMV) and the French Society for Vascular and Endovascular Surgery (SCVE)
18. Traduction et republication de : « Événements thromboemboliques artériels liés au cancer ».
19. Epidemiology and 3‐year outcomes of combined oral contraceptive–associated distal deep vein thrombosis
20. Evaluation of Venous Thromboembolism Recurrence Scores in an Unprovoked Pulmonary Embolism Population: A Post-hoc Analysis of the PADIS-PE trial
21. Update About the Management of Low-Density Lipoprotein Cholesterol and Hypertriglyceridemia in Lower Extremity Peripheral Artery Disease Patients: Consensus of the French Society of Vascular Medicine and the French Society for Vascular and Endovascular Surgery
22. Evaluation of the predictive value of the bleeding prediction score VTE‐BLEED for recurrent venous thromboembolism
23. Cancer-related arterial thromboembolic events
24. Management of venous thromboembolic disease in patients with malignant brain tumours
25. HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome
26. Position du GIHP sur les tests viscoélastiques : quelle place pour quelle indication en situation hémorragique ?
27. Long-term outcomes of isolated superficial vein thrombosis in patients with active cancer
28. Management of bleeding and emergency invasive procedures in patients on dabigatran: Updated guidelines from the French Working Group on Perioperative Haemostasis (GIHP) – September 2016
29. Diagnosis of deep vein thrombosis recurrence: Ultrasound criteria
30. Endovascular Treatment of Post-thrombotic Venous Ilio-Femoral Occlusions: Prognostic Value of Venous Lesions Caudal to the Common Femoral Vein
31. Outpatient management of cancer-related pulmonary embolism: a post-hoc analysis of the HOME-PE trial
32. Impact of an educational program on the quality of life of patients with lymphedema: A preliminary evaluation
33. Anaemia as an independent key risk factor for major haemorrhage in patients treated with vitamin K antagonists: Results of the SCORE prospective cohort
34. Oral anticoagulant safety in family practice: prognostic accuracy of Bleeding Risk Scores (from the CACAO study).
35. Anemia and bleeding in patients receiving anticoagulant therapy for venous thromboembolism: comment
36. Comment estimer le risque d’hémorragies graves chez les patients traités par anticoagulants oraux en soins premiers ? Une étude ancillaire de la cohorte CACAO
37. Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial
38. Gestion péri-opératoire des nouveaux anticoagulants oraux
39. Evaluation of a mobile electronic assistant to aid in fluindione prescription: The INRPlus cluster randomized trial
40. Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Institute/Food and Drug Administration guideline: results of a multicenter management study
41. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013
42. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study
43. Liste des collaborateurs
44. Traitements antithrombotiques après geste de revascularisation
45. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis
46. Induction of the fibrinolytic system by cartilage extract mediates its antiangiogenic effect in mouse glioma
47. Development of a Bayesian estimation tool to determine the optimal duration of apixaban discontinuation before a high‐bleeding risk procedure
48. Devenir à très long terme des patients inclus dans OPTIMEV (étude SPOT) : Volet 1 la mortalité
49. Thrombose et cancer : quel risque et quel pronostic
50. Performances diagnostiques des D-dimères pour exclure l’EP des patients aux urgences ayant la COVID-19
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.